Hepatobiliary complications of cystic fibrosis

Current Gastroenterology Reports

Volumn 6, Issue 3, 2004, Pages 231-239

  Feranchak, Andrew P ^a  

^a CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CHLORIDE CHANNEL; CHLORIDE ION; CYCLIC AMP; TRANSMEMBRANE CONDUCTANCE REGULATOR; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER; CFTR PROTEIN, HUMAN;

APICAL MEMBRANE; BILE ACID SYNTHESIS; BILIARY TRACT DISEASE; CAUCASIAN; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE MARKER; EPITHELIUM CELL; GALLBLADDER EPITHELIUM; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM; HUMAN; LETHALITY; LIFE EXPECTANCY; LIVER FAILURE; LIVER TRANSPLANTATION; PANCREAS DISEASE; PATHOGENESIS; PHENOTYPE; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PROTEIN LOCALIZATION; REVIEW; SCLEROTHERAPY; SCREENING; SECRETORY CELL; SPLENECTOMY; ULTRASOUND; GENETICS; LIVER DISEASE; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

BILIARY TRACT DISEASES; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PORTAL; LIVER DISEASES; LIVER TRANSPLANTATION; MUTATION; PHENOTYPE;

EID: 4544283194     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0013-6     Document Type: Review

References (55)

1. Dodge JA, Morison S, Lewis PA, et al.: Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997, 77: 493-496.
2. Gabriel SE, Brigman KN, Koller BH, et al.: Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994, 266: 107-109.
3. Riordan JR, Rommens JM, Kerem B-S, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245: 1066-1073.
4. Cohn JA, Strong TA, Picciotto MA, et al.: Localization of CFTR in human bile duct epithelial cells. Gastroenterology 1993, 105: 1857-1864.
5. Fitz JG, Basavappa S, McGill J, et al.: Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest 1993, 91: 319-328.
6. Feranchak AP, Sokol RJ: Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 2001, 21: 471-488.
7. McGill J, Gettys TW, Basavappa S, Fitz JG: GTP-binding proteins regulate high conductance anion channels in rat bile duct epithelial cells. J Membr Biol 1993, 133: 253-261.
8. Roman RM, Wang Y, Fitz IG: Regulation of cell volume in a human biliary cell line: calcium-dependent activation of K+ and Cl- currents. Am J Physiol 1996, 271: G239-G248.
9. Roman RM, Feranchak AP, Salter KD, et al.: Endogenous ATP regulates Cl- secretion in cultured human and rat biliary epithelial cells. Am J Physiol 1999, 276: G1391-G400.
10. Feranchak AP, Roman RM, Doctor RB, et al.: The lipid products of phosphoinositide 3-kinase contribute to regulation of cholangiocyte ATP and chloride transport. J Biol Chem 1999, 274: 30979-30986.
11. Feranchak A, Goodwin S, Troetsch, M, et al.: Regulation of secretion in biliary epithelial cells: role of basolateral K+ channels [abstract]. Pediatr Res 2003, 53: 175A.
12. Chari RS, Schutz SM, Haebig JA, et al.: Adenosine nucleotides in bile. Am J Physiol 1996, 270: G246-G252.
13. Feranchak AP, Fitz JG: Adenosine triphosphate release and purinergic regulation of cholangiocyte transport. Semin Liver Dis 2002, 22: 251-262.
14. Feranchak AP, Fitz JG, Roman RM: Volume-sensitive purinergic signaling in human hepatocytes. J Hepatol 2000, 33: 174-182.
15. Knowles MR, Clarke LL, Boucher RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991, 325: 533-538.
16. Parr CE, Sullivan DM, Paradiso AM, et al.: Cloning and expression of a human P2u nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Natl Acad Sci U S A 1994, 91: 3275-3279.
17. Sokol RJ, Durie PR: Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999, 28(Suppl 1): S1-S13.
18. Colombo C, Apostolo MG, Ferrari M, et al.: Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994, 124: 393-399.
19. Zielenski J, Corey M, Rozmahel R, et al.: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999, 22: 128-129.
20. Duthie A, Doherty DG, Donaldson PT, et al.: The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol 1995, 23: 532-537.
21. Henrion-Caude A, Flamant C, Roussey M, et al.: Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002, 36: 913-917.
22. Clarke LL, Grubb BR, Yankaskas J, et al.: Relationship of a noncystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in cftr (-/-) mice. Proc Natl Acad Sci U S A 1994, 91: 479-483.
23. Rozmahel R, Wilschanski M, Matin A, et al.: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996, 12: 280-287.
24. Rohlfs EM, Shaheen NJ, Silverman LM: Is the hemochromatosis gene a modifier locus for cystic fibrosis? Genet Test 1998, 2: 85-88.
25. Friedman K, Ling S, Macek M, et al.: Complex multigenic inheritence influences the development of severe liver disease in CF [A]. Presented at the 15th North American Cystic Fibrosis Conference, Orlando, FL, 2001.
26. Lindblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30: 1151-1158.
27. Colombo C, Apostolo MG, Ferrari M, et al.: Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994, 124: 393-399.
28. Gaskin KJ, Waters DLM, Howman-Giles R, et al.: Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med 1988, 318: 340-346.
29. Colombo C, Battezzati PM, Crosignani A, et al.: Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36: 1374-1382.
30. Roy CC, Weber AM, Morin CL, et al.: Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982, 1: 469-478.
31. Stern RC, Rothstein FC, Doershuk CF: Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1986, 5: 35-40.
32. Colombo C, Bertolini E, Assaisso ML, et al.: Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993, 82: 562-565.
33. Sheth S, Shea JC, Bishop MD, et al.: Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003, 113: 286-292.
34. Williams SG, Evanson JE, Barrett N, et al.: An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995, 22: 513-521.
35. Lenaerts C, Lapierre C, Patriquin H, et al.: Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr 2003, 143: 343-350.
36. Williams SM, Goodman R, Thomson A, et al.: Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002, 57: 365-370.
37. Rattenbury JM, Taylor CJ, Heath PK et al.: Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis. J Clin Pathol 1995, 48: 771-774.
38. Schoenau E, Boeswald W, Wanner R, et al.: High-molecular-mass ('biliary') isoenzyme of alkaline phosphatase and the diagnosis of liver dysfunction in cystic fibrosis. Clin Chem 1989, 35: 1888-1890.
39. Wyatt HA, Dhawan A, Cheeseman P, et al.: Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child 2002, 86: 190-193.
40. Schwarz KB, Rosensweig J, Sharma S, et al.: Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatr Gastroenterol Nutr 2003, 37: 187-191.
41. Augarten A, Berman H, Aviram M, et al.: Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clin Exp Med 2003, 3: 119-123.
42. Gerling B, Becker M, Staab D, Schuppan D: Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med 1997, 336: 1611-1612.
43. Leonardi S, Giambusso F, Sciuto C, et al.: Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis? J Pediatr Gastroenterol Nutr 1998, 27: 603-605.
44. Colombo C, Battezzati PM, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996, 23: 1484-1490.
45. Colombo C, Setchell KD, Podda M, et al.: Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. Pediatr 1990, 117: 482-489.
46. Colombo C, Setchell KD, Podda M, et al.: Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. Pediatr 1990, 117: 482-489.
47. van de Meeberg PC, Houwen RH, Sinaasappel M, et al.: Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease: results of a randomized study with 1- year follow-up. Scand J Gastroenterol 1997, 32: 369-373.
48. Lindblad A, Glaumann H, Strandvik B: A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27: 166-174.
49. Nousia-Arvanitakis S, Fotoulaki M, Economou H, et al.: Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001, 32: 324-328.
50. Efrati O, Barak A, Modan-Moses D, et al.: Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003, 15: 1073-1078.
51. Fridell JA, Bond GJ, Mazariegos GV, et al.: Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003, 38: 1152-1156.
52. Molmenti EP, Squires RH, Nagata D, et al.: Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7: 93-97.
53. Molmenti EP, Squires RH, Nagata D, et al.: Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7: 93-97.
54. Noble-Jamieson G, Valente J, Barnes ND, et al.: Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 1994, 71: 349-352.
55. Couetil JP, Houssin DP, Soubrane O, et al.: Combined lung and liver transplantation in patients with cystic fibrosis: a 4 1/2-year experience. J Thorac Cardiovasc Surg 1995, 110: 1415-1422.